Apyx Medical (NASDAQ:APYX) Stock Price Down 1.9% – Here’s Why

Apyx Medical Corporation (NASDAQ:APYX)’s share price traded down 1.9% on Monday . The company traded as low as $4.55 and last traded at $4.60. 134,598 shares changed hands during trading, a decline of 14% from the average session volume of 156,646 shares. The stock had previously closed at $4.69.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the company. Craig Hallum raised their price objective on Apyx Medical from $5.00 to $6.00 and gave the company a “buy” rating in a research report on Wednesday, March 11th. Wall Street Zen lowered Apyx Medical from a “buy” rating to a “hold” rating in a research report on Sunday, April 26th. BTIG Research upgraded Apyx Medical from a “neutral” rating to a “buy” rating and set a $6.00 price objective for the company in a research report on Wednesday, March 11th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Apyx Medical in a research report on Friday, March 27th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $6.50.

Apyx Medical Trading Down 1.9%

The company has a debt-to-equity ratio of 2.68, a quick ratio of 4.79 and a current ratio of 5.80. The stock’s fifty day moving average is $3.96 and its 200 day moving average is $3.82. The stock has a market cap of $192.60 million, a P/E ratio of -20.91 and a beta of 1.39.

Apyx Medical (NASDAQ:APYX) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.06. Apyx Medical had a negative net margin of 16.40% and a negative return on equity of 88.47%. The firm had revenue of $12.49 million during the quarter, compared to the consensus estimate of $10.53 million.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Nwam LLC bought a new stake in Apyx Medical in the first quarter worth about $47,000. Citadel Advisors LLC bought a new stake in Apyx Medical in the third quarter worth about $28,000. Caprock Group LLC bought a new stake in Apyx Medical in the third quarter worth about $40,000. Hudson Bay Capital Management LP bought a new stake in Apyx Medical in the fourth quarter worth about $73,000. Finally, Osaic Holdings Inc. bought a new stake in Apyx Medical in the second quarter worth about $50,000. Institutional investors own 55.33% of the company’s stock.

About Apyx Medical

Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company’s product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.